Techulon's New MRSA Drug Demonstrates Superior Results
Our research is providing new treatments for intractable diseases
Techulon is Helping Reduce the Risk of Deadly Infections to our US Forces
World Health Organization Declares Antibiotic Resistance a Serious Worldwide Health Threat
Targeted Solutions for Targeted Diseases
Our scalable platform improves discovery outcomes and lowers healthcare expenses.
Our targeted therapeutics opens new treatment options for physicians to improve patient care.
Our current pipeline of therapeutic candidates target infectious diseases with a focus on MRSA.
Techulon Awarded $1.9M to Defeat “Superbugs”
Techulon’s Platform Demonstrates Effective Non-Viral DNA Delivery for in vivo Cardiac Study